NCT07193927View on ClinicalTrials.gov

Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 13, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

June 1, 2027

Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseFatty Liver Disease, NonalcoholicOverweight (BMI > 25)
Interventions
DIETARY_SUPPLEMENT

Lactiplantibacillus plantarum Probiotic Mixture

A daily oral probiotic capsule containing three specific strains of Lactiplantibacillus plantarum (KABP011, KABP012, KABP013) 1,2 billion CFU with vitamin B1, designed to modulate gut microbiota and improve liver health in MASLD patients. It is compared to a placebo in a 6-month, double-blind, mechanistic trial.

DIETARY_SUPPLEMENT

Placebo comparator containing maltodextrin

Placebo comparator containing maltodextrin

Trial Locations (1)

17190

Hospital Universitari Dr. Josep Trueta, Girona

All Listed Sponsors
lead

AB Biotics, SA

INDUSTRY

NCT07193927 - Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial | Biotech Hunter | Biotech Hunter